Loading...
Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis
Trepanowski, Nicole Yim, Rebecca M Wetstone, Rachel MacDonald, Elizabeth Servattalab, Sarah Jacob-George, Subin Harris, John E
Trepanowski, Nicole
Yim, Rebecca M
Wetstone, Rachel
MacDonald, Elizabeth
Servattalab, Sarah
Jacob-George, Subin
Harris, John E
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Case Reports
Publication Date
2023-10-11
Keywords
BMP6
Dynein light chain Tctex-type 3
Dynlt3
LRP5
LRP6
Monoclonal
Pathway
RANKL
Romosozumab
Signaling
Wnt
activity
adverse effect
antibody
bone morphogenetic protein 6
flare
injection
low-density lipoprotein receptor-related protein 5
low-density lipoprotein receptor-related protein 6
medication
osteoporosis
progression
receptor activator of nuclear factor κB ligand
sclerostin
vitiligo
ß-catenin
Dynein light chain Tctex-type 3
Dynlt3
LRP5
LRP6
Monoclonal
Pathway
RANKL
Romosozumab
Signaling
Wnt
activity
adverse effect
antibody
bone morphogenetic protein 6
flare
injection
low-density lipoprotein receptor-related protein 5
low-density lipoprotein receptor-related protein 6
medication
osteoporosis
progression
receptor activator of nuclear factor κB ligand
sclerostin
vitiligo
ß-catenin
Subject Area
Files
Embargo Expiration Date
Link to Full Text
Abstract
Source
Trepanowski N, Yim RM, Wetstone R, MacDonald E, Servattalab S, Jacob-George S, Harris JE. Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis. JAAD Case Rep. 2023 Oct 11;42:26-30. doi: 10.1016/j.jdcr.2023.09.033. PMID: 37965188; PMCID: PMC10641553.
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1016/j.jdcr.2023.09.033
Permanent Link to this Item
PubMed ID
37965188
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright 2023 by the American Academy of Dermatology, Inc. Published
by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.jdcr.2023.09.033